Anzeige
Mehr »
Login
Samstag, 27.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Geheimtipp: Rasanter Aufstieg, Branchenrevolution und Jahresumsatz von 50 Mio. $
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2ACV2 | ISIN: ES0167733015 | Ticker-Symbol: ORN
Frankfurt
26.04.24
08:19 Uhr
1,962 Euro
-0,030
-1,51 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ORYZON GENOMICS SA Chart 1 Jahr
5-Tage-Chart
ORYZON GENOMICS SA 5-Tage-Chart
RealtimeGeldBriefZeit
1,9742,02526.04.
1,9782,02526.04.

Aktuelle News zur ORYZON GENOMICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoOryzon Genomics, S.A.: ORYZON Secures Another Important Patent for its Lead CNS Asset, Vafidemstat183Has received "Intention to Grant" from the European Patent Office For the treatment of aggression and social withdrawal MADRID, Spain and CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Oryzon...
► Artikel lesen
09.04.Oryzon wins FDA approval to begin SCLC treatment trial1
09.04.Oryzon Genomics - FDA green light for SCLC combination trial142With the FDA investigational new drug (IND) application clearance, Oryzon can commence its Phase I/II cooperative research and development agreement (CRADA) trial sponsored by the National Cancer Institute...
► Artikel lesen
05.04.Oryzon Genomics, S.A.: ORYZON to Provide Corporate Progress Updates at Several Events in April2
05.04.Oryzon Genomics - Third time is a charm; INNOVATIVE SME Seal184For the third consecutive time, Oryzon Genomics has received the INNOVATIVE SME Seal from the Spanish Ministry of Science and Innovation. This external recognition highlights Oryzon's key R&D activities...
► Artikel lesen
05.03.Oryzon Genomics - Approaching a period of inflection215Oryzon's FY23 results announcement covered an eventful period for the company's pipeline, capped by the release of top-line data from the Phase IIb PORTICO trial for lead CNS asset vafidemstat. With...
► Artikel lesen
26.02.Oryzon Genomics, S.A.: ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2023103Topline data from vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder (BPD) reported with promising results in secondary endpoints of overall severity and control of agitation/aggressionCompany...
► Artikel lesen
26.02.ORYZON GENOMICS, S.A.: The Company reports on the Award issued within the arbitration proceedings initiated against Cofina SGPS, S.A., regarding the sale of all the shares from Vertix SGPS, S.A3
23.02.ORYZON GENOMICS, S.A.: Share Buyback Program: transactions conducted between 16 February 2024 and 22 February 20241
05.02.Oryzon Genomics, S.A.: ORYZON to Provide Corporate Progress Updates at Several Events in February-March964Keystone Symposia Epigenetic Mechanisms and Cancer TreatmentBio-Neuroscience17th Annual European Life Sciences CEO Forum BIO-Europe Spring 2024 MADRID, Spain and BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE)...
► Artikel lesen
02.02.ORYZON GENOMICS, S.A.: ARIMA REAL ESTATE reports the transactions carried out under its share buyback plan between January 26 and February 1, 2024.1
29.01.Oryzon Genomics - KOL event: Offering a real-world solution in BPD236Oryzon hosted a key opinion leader (KOL) event highlighting the potential of vafidemstat in borderline personality disorder (BPD). The KOLs discussed the limited options for treating BPD, as there are...
► Artikel lesen
19.01.Oryzon Genomics, S.A.: ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 20241
10.01.Oryzon Genomics - PORTICO update with planned FDA EoP2262Oryzon Genomics has announced top-line results for the Phase IIb trial (PORTICO) assessing vafidemstat in borderline personality disorder (BPD), and while the primary endpoints (Borderline Personality...
► Artikel lesen
07.01.Oryzon med fails to improve borderline personality disorder, but executives see a path with new endpoints2
05.01.Oryzon Genomics, S.A.: ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat in Borderline Personality Disorder (BPD)206Company to host Conference Call and live Webcast on Sunday, January 7, 2024 at 5:30 pm PT. An executive summary of the data to be presented at the 7th Sachs Annual Neuroscience Innovation Forum,...
► Artikel lesen
05.01.ORYZON GENOMICS, S.A.: ORYZON presents topline results from vafidemstat's Phase IIb PORTICO trial in borderline personality disorder.2
03.01.Oryzon Genomics, S.A.: ORYZON to Provide Corporate Progress Updates at Several Events in January2817th Sachs Annual Neuroscience Innovation Forum13rd Annual LifeSci Advisors Corporate Access EventBiotech Showcase-2024 42nd Annual J.P. Morgan Healthcare ConferenceInvest Securities Biomed Forum 2024...
► Artikel lesen
05.12.23Oryzon Genomics - Grant to bolster ALS pipeline, add funding347Oryzon has announced the receipt of a $0.5m grant from the Amyotrophic Lateral Sclerosis (ALS) Association to support the regulatory clinical development of the company's histone deacetylase 6 (HDAC6)...
► Artikel lesen
04.12.23Oryzon Genomics, S.A.: ORYZON Awarded with a Grant for ORY-4001 From the ALS Association in the U.S.221To explore Oryzon's clinical candidate ORY-4001 in ALS The ALS Association to provide 500,000 USD funding MADRID, Spain and BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code:...
► Artikel lesen
Seite:  Weiter >>
35 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1